Tumour marker
A tumour marker, also called a cancer biomarker, is a substance found in the body which concentration in the blood or other body fluid increases when cancer is present. The tumour marker may be produced by the cancer cells themselves or by healthy cells in response to the cancer. Tumour markers are usually proteins and are often produced in small amounts even in people without cancer. The term tumour marker may also be used to mean typical molecular changes in cancers, like ALK rearrangement and overexpression in NSCLC.
Tumour markers are not used for diagnosis of cancer, as they are not specific (can be elevated even without cancer) and are not sensitive (not all cancers cause tumour marker elevation). Some are used for screening, the prototypical example being PSA for prostate cancer, but because of the low specificity and sensitivity, this is controversial.
One of the main uses tumour markers is to monitor an already diagnosed cancer, often after treatment Following successfull cancer treatment, one expects the tumour marker level to drop or even normalise. If this does not occur, one can often assume that treatment was unsuccessfull. Following treatment, one can monitor the tumour marker regularly. A sudden increase in tumor marker is a sign of cancer recurrence.
However, as already mentioned, tumour markers are not sensitive, meaning that some cancer do not produce tumour markers. In these cases, tumour markers cannot be used to evaluate treatment response or monitor for recurrence.
Another main use of tumour markers is to evaluate the prognosis of a newly diagnosed cancer. If a cancer is diagnosed (or highly suspected), a significantly elevated tumour marker confers a worse prognosis than a non-elevated or only slightly elevated tumour marker, and may be a sign of locally advanced or metastatic disease.
Table of most important tumour markers
| Marker | Associated cancers |
|---|---|
| Human chorionic gonadotropin (hCG) | Trophoblastic tumours, nonseminomatous testicular tumours |
| α-foetoprotein (AFP) | Liver cell cancer, nonseminomatous testicular tumours |
| Carcinoembryonic antigen (CEA) | Carcinomas of colon, pancreas, lung, stomach, heart |
| Prostate specific antigen (PSA) | Prostate cancer |
| CA-125 | Ovarian cancer |
| CA-19-9 | Colon cancer, pancreatic cancer |
| CA 15-3 | Breast cancer |
| Calcitonin | Medullary carcinoma of thyroid |
| Catecholamine and catecholamine metabolites | Pheochromocytoma |
| Ectopic hormones | Small-cell lung carcinoma, hepatocellular and pancreatic carcinomas |
| Prostatic acid phosphatase | Prostate cancer |
| Neuron-specific enolase | Small-cell lung cancer, neuroblastoma |
| Immunoglobulins | Multiple myeloma |
Those which are bolded are the most important.
Prostate specific antigen
Prostate specific antigen (PSA) is a protein produced in the prostate. It is elevated in prostate cancer but also prostatitis and benign prostatic hyperplasia. It should not be measured after digital rectal examination, as this artificially elevates the PSA.
PSA in plasma is mostly bound to a carrier protein, while a small fraction is free. The fraction that is free is lower in malignancy than in benign causes of elevated PSA and can be used to help differentiate them.
PSA is sometimes used for screening for prostate cancer, but this is controversial. Screening decreases mortality from prostate cancer but also causes overtreatment, as many of those who will receive cancer therapy (with all the complications and side effects it causes) due to detection of prostate cancer on screening would never have developed a clinically significant cancer.